<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jung N</submitter><funding>the Korea Health Industry Development Institute (KHIDI), Ministry of Health and Welfare</funding><pagination>e0277218</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9635733</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(11)</volume><pubmed_abstract>Mesenchymal stem cells (MSCs) are known to be able to modulate immune responses, possess tissue-protective properties, and exhibit healing capacities with therapeutic potential for various diseases. The ability of MSCs to secrete various cytokines and growth factors provides new insights into autoimmune-diseases such as rheumatoid arthritis (RA). RA is a systemic autoimmune disease that affects the lining of synovial joints, causing stiffness, pain, inflammation, and joint erosion. In recent years, MSCs-based therapies have been widely proposed as promising therapies in the treatment of RA. However, the mechanism involved in disease-specific therapeutic effects of MSCs on RA remains unclear. To clarify the mechanism involved in effects of MSCs on RA, proteomic profiling was performed using</pubmed_abstract><journal>PloS one</journal><pubmed_title>LC-MS/MS-based serum proteomics reveals a distinctive signature in a rheumatoid arthritis mouse model after treatment with mesenchymal stem cells.</pubmed_title><pmcid>PMC9635733</pmcid><funding_grant_id>HI20C0675</funding_grant_id><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Park H</pubmed_authors><pubmed_authors>Jung N</pubmed_authors><pubmed_authors>Kong T</pubmed_authors><pubmed_authors>Park S</pubmed_authors><pubmed_authors>Seo WM</pubmed_authors><pubmed_authors>Kang KS</pubmed_authors></additional><is_claimable>false</is_claimable><name>LC-MS/MS-based serum proteomics reveals a distinctive signature in a rheumatoid arthritis mouse model after treatment with mesenchymal stem cells.</name><description>Mesenchymal stem cells (MSCs) are known to be able to modulate immune responses, possess tissue-protective properties, and exhibit healing capacities with therapeutic potential for various diseases. The ability of MSCs to secrete various cytokines and growth factors provides new insights into autoimmune-diseases such as rheumatoid arthritis (RA). RA is a systemic autoimmune disease that affects the lining of synovial joints, causing stiffness, pain, inflammation, and joint erosion. In recent years, MSCs-based therapies have been widely proposed as promising therapies in the treatment of RA. However, the mechanism involved in disease-specific therapeutic effects of MSCs on RA remains unclear. To clarify the mechanism involved in effects of MSCs on RA, proteomic profiling was performed using</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-05-28T01:01:40.025Z</modification><creation>2024-11-19T22:26:19.783Z</creation></dates><accession>S-EPMC9635733</accession><cross_references><pubmed>36331907</pubmed><doi>10.1371/journal.pone.0277218</doi></cross_references></HashMap>